Real-world use affirms benefit of triple therapy in COPD
21 Apr 2021
byJairia Dela Cruz
Inhaled triple therapy containing beclomethasone dipropionate, formoterol fumarate, and glycopyrronium helps improve lung function and symptom control, as well as cut the frequency of exacerbations, in patients with chronic obstructive pulmonary disorder (COPD) treated in a real-world setting, according to data from the TRICOP noninterventional study.